Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-08-21
1999-05-25
Azpuru, Carlos
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514654, 514655, 424422, A01N 3302
Patent
active
059069961
ABSTRACT:
2,3,2 Tetramine (3,7-diazanonane-1,9-diamine) is propounded for the treatment of Parkinson's Disease and dementias characterized by mitochondrial damage in view of this compound's ability to completely neutralize the dopainine-depriving effect of MPTP in laboratory animals up to 12 hours post MPTP injection, and to retain partial protection at suboptimal tissue levels for up to 36 hours. The effect of injecting combinations of MPTP and/or reducing agents and/or xenobiotics and/or depigmenting agents on Dopamine, Norepinephrine, Serotonin and Epinephrine levels demonstrated that MPTP and MPP+ act as reducing agents that mobilize copper and calcium, and sequester iron, and that the vulnerability of dopamine to these types of neurotoxins and to xenobiotics and metals can be corrected by administration of 2,3,2 tetramine that appears to redistribute metals between diverse storage pools and free metals in cytosol and regulate receptor mediated events, among other antidotal effects analogous to those of some of the endogenous polyamines.
REFERENCES:
Schlaug et al, Neurological Impairment and Recovery in Wilson's Disease, J. Neur. Sci. vol. 136, pp. 129-139, Mar. 1996.
Robbins et al, Pathologic Basis of Disease, 3rd ed., pp. 932-933 and 1423, 1984.
Tan et al, An In Vitro Study of Cpper and Copper Chelators on the Crayfish Procambarus-ClarkII Stretch Receptor, Neuropharmacology 23 (6), pp. 683-690, 1984.
Borthwick et al, Copper Chelating Agents, J. Lab. Clin. Med. 95 (4), pp. 575-580, 1980.
Abraham C.R. et al, A Calcium-Activated Protease . . . B-Protein. Biochem. Biophys. Res. Commun. (1991, 174, 790-96.
Abraham C.R. et al., Studies on the Proteolytic Degradation . . . Alzheimer's Brain. Ann. New York Acad. Sci. (1991, 640, 161-65.
Abraham C.R. et al., Purification and Cloning of Brain Proteases . . . Precursor Protein. Ann. New York Acad. Sci. (1992) 674, 174-179.
Alam, Z.I. et al., Purification and Cloning of Grain Proteases . . . Precursor Protein. Ann. New York acad. Sci. (1992) 674, 174-179.
Asenjo A. et al., Cytosiderose et Depots de fer Dans le Noyau . . . de Parkinson. Etude Clinique et Experimentale. Rev. Neurologique (1969), 121(6) 581-92.
Baeza I. et al. Possible Prebiotic Significance of Polyamines . . . Properties of DNA. Orig. Life Evol. Spec. (1992), 21, 225-42.
Barbeau A. et al. Comparative Behavioral, Biochemical and Pigmentary Effects . . . in Rana Pipiens. Life Sci. (1985) 37, 1529-38.
Barbeau A. et al., Studies on MPTP, MPP.sup.+ and Paraquat in Frogs and In Vitro. In MPTP: . . . Syndrome. Ed by S.P. Markey, Academic Press (1986), 85-103.
Bellett a.J.D., et al., Spermine and Aminoguanidine Protect Cells . . . The Cell Cycle. Chromosoma (Berl.) (1982), 84, 571-83.
Beneviste, M. et al. Multiple Effects of Spermine on . . . Hippocampal Neurones. Jour. Physiol. (1993), 464, 131-63.
Black R.A. et al., Preaspartate Protease . . . Interleukin-1B. Jour. Biol. Chem. (1989), 264, 5323-26.
Borthwick TR., et al., A Comparison of Cupruretic Responses . . . d-Penicillamine. Jour. Lab. Clin. Med. (1980), 95 (4), 575-80.
Bradley W. G., et al., A New Hypothesis of . . . Lateral Sclerosis. Arch. Neurol. (1982), 39, 677-80.
Brantl V., et al., Novel Opioid Peptides Derived from Mitochondrial . . . Cytocrophins. Eur. Jour. Pharmacol. (1985), III, 293-94.
Chu P., et al. Polyamines Promote Regeneration . . . Hippocampal Neurons. Brain Res. 1995, 673, 233-41.
Clayton D.A., et al., The Absence of a Pyrimidine Dimer . . . Mitochondria. Proc. Natl. Acad. Sci. (1974), 71, 2777-81.
Cortopassi, G. et al., Modelling the Effects of Age . . . Superoxide Cell Death. Biochem. Biophys. acta (1995), 1271-76.
Corsini G.U., et al. 1-Methyl-4-Phenyl 1,2,3,6 Tetrahydropyridine . . . diethylthiocarbamate. Eur. Jour. Pharmacol. (1985), 119: 127-28.
Delacourte A. et al., Modelling the Effects of Age-Related mtDNA Mutation . . . Superoxide Cell Death. Biochem. Biophys. Acta (1995), 1271-76.
Corsini G.U., et al., 1-Methyl-4- Phenyleferential Localization . . . Alzheimer's Disease. Neurosci. let. (1988), 92 (3), 247-53.
Di Monte, D.A., Mitochondrial DNA and Parkinson's Disease. Neurology (1991), 41 Suppl 1; 38-43.
Dubin, D.T., Evidence for Conjugation Between Glutathione and Polyamines in E. Coli. Biochem. Biophys. Res. Commun. (1959), 1 (5), 262-65.
Earle K.M., Studies on Parkinson's Disease Including X Ray . . . Brain Tissue. J. Neuropathol. Exper. Neurol. (1968), 27 (1), 1-14.
Edelstein C., et al., Demonstration that the Enzyme that Converts . . . Arch. Biochem. Biophys. (1988), 267, 23-30.
Eizirik D.L., et al., Cycad Toxin-Induced Damage of Rodent . . . B-Cells. Biochem. Pharmacol. (1995), 50(3), 355-65.
Ekstrom G. et al., Comparative Toxicity and Antioxidant Activity . . . Liver Microsomes. arch. Biochem. Biophys. 1987, 255 (1), 14-18.
Farrar J.R. et al., Effects of Copper on the Binding of Agonists . . . Rat Brain. Biochem. Pharmacol. 91984), 33 (18), 2849-56.
Fitzgerald G.B., Sequential Inhigitory Effects of Antitumor Agents . . . Synthetic Enzymes. Biochem. Pharmacol. (1986), 35 (2), 271-75.
Gilad G., et al., Polyamines Induce Precocious Development . . . Growth Factors. Int. Jour. Devl. Neurosci. (1989), 7 (6) 641-53.
Goering P.L., et al., Induction of Hepatic Metallothionein . . . Chelating Agents. Toxicol. Appl. Pharmacol. (1985), 80, 467-72.
Gomirato G., et al., A Biochemical Glial Error in Parkineson's Disease. Brain (1963), 86, 773-80.
Grabie V., et al., Paraquat Uptake . . . Cell Line, IEC-6. Toxicol. Applied Pharmacol. (1993), 122(1), 95-100.
Ha H.D., et al., Structural Specificity of Polyamines . . . Reactive Oxygen Species. Biochem. Biophys. Res. Commun. (1998), 244, 298-303.
Hung H.C., et al., The Mesolimbic Dopaminergic Pathway . . . BDNF Gene Expression. Molec. Brain Res. (1996), 41, 16-26.
Janne J. et al., Spermidine and Spermine in Rat Tissues at Different Ages. Acta Physiol. Scand. (1964), 62, 352-58.
Kelner M.J. et al., Inactivation of Intracellular . . . Methemoglobin Formation Free RAdical Biol. Med. (1989), 6 (4), 355-60.
Khan A.U., et al., Aproposed Function for Spermine and Spermidine . . . Singlet Oxygen. Proc. Natl. Acad. Sci. (1992), 89, 11426-27.
Khan A.U., et al., Spermine and Spermidine Protection of Plasmid DNA . . . Induced by Singlet Oxygen. proc. Natl. acad. sci. (1992), 89, 11428-30.
Kooistra T., et al., In Vitro Studies on Origin and Site of Action . . . Apoprotein A-1. FEBS Lett. (1984), 170, 109-13.
Kremzner L.T. Polyamine Metabolism in Normal and Neoplastic Neural Tissue . . . , Neoplastic Growth. Proceedings of a symposium of the Nat'l Cancer Institute Ed. DE.H. Russell. Raven Press. New York 1973, pp. 27-40.
Lambert C.W., et al., Defective DNA Synthesis and/or Repair . . . Mammalian Cells. Ed. Muriel W. Lambert & Jaques Laval. NATO ASI Series A Life Sciences vol. 182, 19 182,pp. 501-521.
Levy D.I. et al., Redox Modulation of NMDA Receptor-Mediated . . . Central Neurons. Neurosci. Lett. (1990), 110 (3), 291-96.
Li J.C., et al., Deficient Repair of DNA Lesions . . . Fibroblasts. Biochem. Biophys. Res. Commun. (1985), 129, 733-38.
Llorens-Cortes C., et al., Enkephalinergic Markers in Substantia Nigra . . . Parkinsonian Subjects. Jour. Neurochem. (1984), 43, 874-77.
Mancon M., et al., On Teh Presence of Polyamines in Mitochondria. Ital. Jour. Biochem. (1990), 39, 278A-279A.
Marshall K.A. et al., Upregulation of the Anti-Apoptotic Protein BCL-2 . . . Lewy Body Disease. Biochem. Biophys. Res. Commu. (1997), 240, 84-87.
Maruyama w., et al., An Endogenous Dopaminergic Neurotoxin . . . SH-SY5Y Cells. Jour. Neurochem. (1997), 69 (1), 322-29.
McCormack J.G. Effects of Spermine on Mitochondrial . . . Dehydrogenases Respond. Biochem. Jour. (1989), 264, 167-74.
McGurk, J.F., et al., Polyamines Potentiate Responses . . . Xenopus Oocytes. Proc. Natl. Acad. Sci. (1990), 87, 9971-4.
MEzzetti G., et al., Polyamines and the Catalytic Domain . . . Kinase C. Life Sci. (1988), 42, 2293-98.
Miyako K., et al., The Content of Intracellular Mitochondrial DNA . . . Ion (MPP.sup.+). Jour. biol. Chem. (1997), 272, 15, 96505-08.
Miyata t., et al., Molecular Clock of Silent Substitutions . . .
Azpuru Carlos
Buchaca John D.
Channavajjala Lakshmi
Charmasson Henri J. A.
LandOfFree
Tetramine treatment of neurological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetramine treatment of neurological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetramine treatment of neurological disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-401452